Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R C Knapp

Showing results (41-50 of 90) with videos related to

Pageof 9
Sort By:
The Journal of Clinical Investigation|November 1, 1981
Reactivity of a monoclonal antibody with human ovarian carcinomaR C Bast, M Feeney, H Lazarus, et al.
Fertility and Sterility|May 1, 1986
Elevated serum concentrations of CA-125 in patients with advanced endometriosisR L Barbieri, J M Niloff, R C Bast, et al.
Cancer|March 15, 1980
Radiation therapy in stage II ovarian carcinoma: the influence of histologic gradeP M Mauch, R L Ehrmann, C T Griffiths, et al.
Gynecologic Oncology|September 1, 1991
Effect of differentiation agents on expression of CA 125, alkaline phosphatase, and cytokeratins in human ovarian adenocarcinoma cells (OVCA 433)S E Brooks, J Timmerman, C C Lau, et al.
Radiology|March 1, 1982
The role of postoperative local or regional irradiation in the treatment of stage I ovarian cancerW D Powlis, P Mauch, R L Ehrmann, et al.
American Journal of Obstetrics and Gynecology|April 15, 1984
Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervixJ M Niloff, T L Klug, E Schaetzl, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 1, 1992
Analysis of cytotoxicity of 131I-labelled OC125 F(ab')2 on human epithelial ovarian cancer cell linesE Schneider-Gädicke, J L Humm, C C Lau, et al.
Obstetrics and Gynecology|February 1, 1987
CA 125 for the monitoring of ovarian carcinoma during primary therapyP T Lavin, R C Knapp, G Malkasian, et al.
American Journal of Obstetrics and Gynecology|November 1, 1989
Influence of human antimurine antibody on CA 125 levels in patients with ovarian cancer undergoing radioimmunotherapy or immunoscintigraphy with murine monoclonal antibody OC 125M G Muto, E M Lepisto, A D Van den Abbeele, et al.
Gynecologic Oncology|July 1, 1990
Antigenic heterogeneity in human ovarian cancerW R Welch, J M Niloff, D Anderson, et al.
Pageof 9

Showing results (41-50 of 90) with videos related to

Sort By:
Pageof 9
The Journal of Clinical Investigation|November 1, 1981
Reactivity of a monoclonal antibody with human ovarian carcinomaR C Bast, M Feeney, H Lazarus, et al.
Fertility and Sterility|May 1, 1986
Elevated serum concentrations of CA-125 in patients with advanced endometriosisR L Barbieri, J M Niloff, R C Bast, et al.
Cancer|March 15, 1980
Radiation therapy in stage II ovarian carcinoma: the influence of histologic gradeP M Mauch, R L Ehrmann, C T Griffiths, et al.
Gynecologic Oncology|September 1, 1991
Effect of differentiation agents on expression of CA 125, alkaline phosphatase, and cytokeratins in human ovarian adenocarcinoma cells (OVCA 433)S E Brooks, J Timmerman, C C Lau, et al.
Radiology|March 1, 1982
The role of postoperative local or regional irradiation in the treatment of stage I ovarian cancerW D Powlis, P Mauch, R L Ehrmann, et al.
American Journal of Obstetrics and Gynecology|April 15, 1984
Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervixJ M Niloff, T L Klug, E Schaetzl, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 1, 1992
Analysis of cytotoxicity of 131I-labelled OC125 F(ab')2 on human epithelial ovarian cancer cell linesE Schneider-Gädicke, J L Humm, C C Lau, et al.
Obstetrics and Gynecology|February 1, 1987
CA 125 for the monitoring of ovarian carcinoma during primary therapyP T Lavin, R C Knapp, G Malkasian, et al.
American Journal of Obstetrics and Gynecology|November 1, 1989
Influence of human antimurine antibody on CA 125 levels in patients with ovarian cancer undergoing radioimmunotherapy or immunoscintigraphy with murine monoclonal antibody OC 125M G Muto, E M Lepisto, A D Van den Abbeele, et al.
Gynecologic Oncology|July 1, 1990
Antigenic heterogeneity in human ovarian cancerW R Welch, J M Niloff, D Anderson, et al.
Pageof 9